Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib
Rybrevant®(阿米萬單抗-Vmjw)加Lazcluze™(拉澤替尼)在整體生存期方面顯示出與厄洛替尼相比的統計學顯著性和臨牀意義的改善
Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib
Rybrevant®(阿米萬單抗-Vmjw)加Lazcluze™(拉澤替尼)在整體生存期方面顯示出與厄洛替尼相比的統計學顯著性和臨牀意義的改善
使用瀏覽器的分享功能,分享給你的好友吧